Anti-L1CAM radioimmunotherapy with 161Tb shows the potential to kill ovarian cancer stem cells. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Anti-L1CAM radioimmunotherapy with 161Tb shows the potential to kill ovarian cancer stem cells.

Caption

Graphical Abstract: Anti-L1CAM radioimmunotherapy with 161Tb shows the potential to kill ovarian cancer stem cells. Researchers confirmed the presence of L1CAM+/CD133+ ovarian cancer stem cells in patient samples for the first time. Anti-LCAM treatment with 161Tb resulted in higher cellular toxicity. Anti-L1CAM radioimmunotherapy with 161Tb successfully eliminated L1CAM+/CD133+ ovarian cancer stem cells in mouse models, which completely prevented tumor growth. These results signify a key proof of concept that 161Tb could successfully kill cancer stem cells, addressing this main clinical challenge in cancer care.

Credit

Images created by Jürgem Grünberg, PhD, and Tihomir Todorov, PhD, Center of Radiopharamaceutical Sciences, Center for Life Sciences, Paul Scherrer Institut.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.